Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Relapsing Giant Cell Arteritis
2013-002778-38Phase 2Terminated
- Sponsor
- Servier
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Gevokizumab arm with Placebo arm (2 arms). Primary endpoint: Proportion of responders to treatment. Started Oct 2013; status: terminated.
02
Drugs
gevokizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2013-002778-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002778-38.